Companies have scant financial incentive to develop new antibiotics. Will the NIH continue to support relevant research?

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you ...

The clinical benefits of exercise-based cardiac rehabilitation have been less clear for patients with Afib. A meta-analysis ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 10 Best and Safe Dividend Stocks to Buy Now. Bristol-Myers Squibb Company (NYSE:BMY) presents a strong case for investors looking for both ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

The company will pay $140.6 million to settle claims that it illegally exported products to China. Separately, Cadence posted higher revenue in the second quarter and boosted its full-year earnings ...